DrugMonkey doesn't think much of the new NIH rules to address financial conflict of interest among researchers. In fact, he says, the tighter rules "will do absolutely nothing about real COI." For one thing, DrugMonkey says, lowering the reporting threshold from $10,000 to $5,000 won't do anything about the PIs who caused scandal and were investigated by Congress for making hundreds of thousands of dollars from big pharma without reporting it.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.